



Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: <https://astallabs.com/>

CORRIGENDUM TO THE NOTICE OF EXTRA ORDINARY GENERAL MEETING

We draw attention of all the Members of **Astal Laboratories Limited** (Formerly known as Macro International Limited) (“**the Company**”) to the Notice dated 9th October, 2025, convening the Extra Ordinary General Meeting (“**EGM**”) of the Company (“**EGM Notice**”) scheduled to be held on Thursday, 6th November, 2025 at 3.00 p.m. IST, through Video Conferencing (“**VC**”) / Other Audio-Visual Means (“**OAVM**”). The EGM Notice has already been electronically sent to all the members of the Company on Monday, 13th October, 2025 whose email addresses were registered with the Company and/ or Depository Participant(s) in compliance with the provisions of the Companies Act, 2013 (“**the Act**”), the rules made thereunder, and the circulars issued by the Ministry of Corporate Affairs (“**MCA**”) and the Securities and Exchange Board of India (“**SEBI**”) (collectively referred to as “**Circulars**”).

The Company had applied to BSE Limited (BSE) for *in-principle approval* for the issuance of 3,04,58,187 equity shares on a preferential basis for consideration other than cash (i.e., share swap).

During BSE’s review, it was observed that Ms. Niharika Bansal, one of the proposed allottees (Sr. No. 126 in the resolution), sold 100 equity shares of the Company on July 17, 2025. This sale occurred within 90 trading days preceding the relevant date, violating Regulation 159(1)(c) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“**SEBI ICDR Regulations**”). As a result, Ms. Niharika Bansal is disqualified from receiving shares under the preferential allotment and will not be allotted 32,555 equity shares that were proposed to be issued to her.

Since the preferential issue was intended to facilitate the acquisition of 100% stake in Sriven Pharmachem India Private Limited through a share swap, the Company has decided that, instead of issuing shares, it will settle the transaction in cash for that portion.

Accordingly, this Corrigendum to the EGM Notice (“**Corrigendum**”) is being issued to provide certain clarifications, modifications, and updates to the EGM Notice, pursuant to the observations of BSE, and in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“**ICDR Regulations**”), the applicable provisions of the Act, the rules made thereunder, and the MCA Circulars.

As the Members are aware, the Company is offering remote e-voting facility to enable the Members to cast their votes on all resolutions proposed to be transacted at the EGM. In order to facilitate informed decision-making, whether through remote e-voting or during the EGM via VC/OAVM, the Company considers it appropriate to bring to the Members’ attention the updated factual position through this Corrigendum.

This Corrigendum shall form an integral part of the original EGM Notice and shall be read in conjunction therewith.

Below are the modifications in the Resolution and Explanatory Statement of Item No.: 02 of the EGM Notice:

1. The details of Ms. Niharika Bansal under Sr. No. 126 wherever appearing in the Resolution and Explanatory Statement is now deleted.

Accordingly, the number of Equity Shares to be issued shall now be read as 3,04,25,632 and Issue size shall now be read as 276,87,32,512/- (Rupees Two Hundred Seventy Six Crore Eighty Seven Lakh Thirty Two Thousand Five Hundred and Twelve only)

2. **Under Explanatory Statement:**

- i. **Table under Point No. 10 i.e. Shareholding pattern before and after Preferential Issue would now be read as follows:**

Sr. No.	Category	Pre Preferential Issue*		Post Preferential Issue of 3,04,25,632 Equity Shares under current Preferential Issue		Post Preferential Issue of 3,04,25,632 Equity Shares under current Preferential Issue and assuming full conversion of 27,90,000 warrants allotted on 27th November, 2024 into equity shares.	
		No. of shares held	% of share holding	No. of shares held	% of share holding	No. of shares held	% of share holding
A	Promoters Holding	19,59,284	18.19	19,59,284	4.76	19,59,284	4.45
B	Non-promoters' holding	88,10,716	81.81	3,92,36,348	95.24	4,20,26,348	95.55
C	Non Promoter & Non Public	-	0.00	-	0.00	-	0.00
	GRAND TOTAL	1,07,70,000	100.00	4,11,95,632	100.00	4,39,85,632	100.00

ii. Accordingly, the Individual shareholding in terms of % in Table under Point No. 12 i.e. Identity of the natural persons who are the ultimate beneficial owners of the shares proposed to be allotted and/or who ultimately control the proposed allottees, the percentage of post preferential issues that may be held by them and change in control if any in the issuer consequent to the preferential issues will be changed to that extent.

With effect from the date of this Corrigendum, the EGM Notice shall always be read in conjunction with this Corrigendum which is also being uploaded on the website of the Company at www.astallabs.com and on the website of CDSL at www.evotingindia.com, and Stock Exchanges i.e. www.bseindia.com.

All other contents of the EGM Notice, save and except as amended / clarified by this Corrigendum, shall remain unchanged.

**By order of the Board of Directors,
For Astal Laboratories Limited**

Sd/-
Mahendra Kumar
Company Secretary & Compliance Officer
Membership No.: A71224

Date: 4th November, 2025
Place: Hyderabad